In lung cancer, the most relevant therapeutic targets include ROR1, EGFR, PD-L1, CD80/CD86, mucin 1 (MUC1), mesothelin (MSLN), carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA) and human epidermal growth factor receptor 2 (HER2) (139, 152). Here, ERBB2 is linked to lung cancer.